联系我们

论文查询结果	返回搜索

论文编号：	9833
作者编号：	2120152827
上传时间：	2017/12/13 16:00:05
中文题目：	B生物科技公司融资策略
英文题目：	B biotech company financing strategy
指导老师：	齐岳
中文关键字：	种质库；中小企业；融资方式；风险控制
英文关键字：	Gene bank; Small and medium-sized enterprises; Financing methods; Risk control
中文摘要：	B公司是国内专业从事中药材及相关经济作物的品种改良及选育，珍贵濒危中药材人工培育的高新技术企业。公司依托于国内知名院校科研技术团队，旨在进行生物科技成果的生产力转化，打造成为中国中药材及相关经济作物品种改良，选育及种苗培育的高端品牌科技型公司。未来十年，公司定位于集研发、生产、服务于一体，集互联网、物联网等信息技术于一身，高度专业化、信息化、智能化的科技型企业，为大健康产业提供一份坚实的力量。最终打造成为以研究院的形式、以公司化的运作方式进行科研成果转化的平台，成为围绕生物科技领域发展的企业领袖。党的十八大以来，扶持中医药和民族医药事业的发展成为建设健康中国的时代强音。中医药是中华民族优秀传统文化的重要组成部分。随着国家中医药“大健康”规划的实施，以及公众“绿色”中药观念的兴起，极大地拉动了优质中药材、中药饮片以及中药提取物的内需；此外随着中国《中医药“一带一路”发展规划》的实施，推动了海外中医药产业的快速发展，综合以上因素，使得消费市场上对优质中药材的需求急剧上升。在中医药市场如此火热的当下，B公司迎来的不单单是迅速发展的机遇，更多的是面临着越来越激烈的市场竞争。如果想要在竞争中求得发展，那么加大研发投入，开发高附加值的产品，扩大生产规模，抢占市场先机将变得尤为重要。 B公司通过数年的技术积淀和资金积累，在现有产业链中所产生的纯利润，在速度和规模上尚不能满足高科技企业的增长需求，特别是在具有较高技术投入要求和时间成本投入的生物科技领域。与此同时，高新技术的生物科技企业自身的某些特质也在一定程度上决定了这类中小型企业面临着融资难的问题，这同时也是中小型企业生存周期普遍偏低的主要原因之一。为了针对性解决这一类问题，同时也是为了能够使企业积极适应国内相关政策，加速企业发展及规模经济的形成，拓宽企业未来业务发展空间，本文欲以B公司为研究对象，从公司不同发展阶段和各阶段的资金需求，并结合融资模式，融资渠道，如何优化资本结构以及如何提高资本效率的角度来加以分析。
英文摘要：	Company B is a high-tech enterprise which is specialized in the improvement and breeding of Chinese medicinal materials and related economic crops. Company relies on domestic well-known colleges and universities scientific research and technical team, designed to biological scientific and technological achievements into productivity, make traditional Chinese medicine in China and the relevant economic crop variety improvement, breeding and seedling cultivation of high-end brand technology-based companies. In the next decade, the company locate in integrating research and development, production, services, information technology such as the Internet, the Internet of things in one, a highly specialized, informationization, intelligent science and technology enterprises, for a big health industry to provide a solid strength. Finally, it becomes a platform to transform the scientific research results in the form of research institute and the way of corporation operation, and become the leader of the enterprise in the field of biotechnology. Since the 18th national congress of the communist party of China (CPC), the development of traditional Chinese medicine and national medicine has become an era of healthy China. Traditional Chinese medicine, as the traditional national essence, is an important part of Chinese traditional culture. As the national planning the implementation of the "great health" of traditional Chinese medicine, the rise of "green" concept of Chinese traditional medicine, and public greatly boost the quality of Chinese herbal medicine, Chinese medicine yinpian and traditional Chinese medicine extract domestic demand; In addition, as China's "Chinese medicine" area "development plan", promoted the rapid development of overseas Chinese medicine industry, comprehensive above factors, makes a sharp rise in the consumer market demand for high-quality Chinese herbal medicine. In the current market of TCM, company B is facing not only the opportunity of rapid development, but also the increasingly fierce market competition. If you want to develop in the competition, it will become more important to increase r&d investment, develop high value-added products, expand production scale, and preempt the market. B company through several years of technology accumulation and capital accumulation, the net profit generated by the existing industry chain, on the speed and scale is still cannot meet the demand of the growth of the high-tech enterprises, especially in high technical requirements and time cost input of biotechnology. At the same time, the high and new technology of biological science and technology enterprises own qualities and to a certain extent, determines the financing problems of small and medium-sized enterprises facing problems, it is also one of the main reasons for small and medium-sized enterprise survival cycle generally low. To targeted to solve this kind of problem, is also to be able to make the enterprises to actively adapt to the domestic policies, accelerate the enterprise development and the formation of scale economy, broaden the enterprise future business development space, this article tries to B company as the research object, from the different stages of development and capital needs at each stage, and connecting with the financing, financing channels, how to optimize capital structure and how to improve the efficiency of capital from the point of view of analysis.
查看全文：	预览  下载(下载需要进行登录)